Drug-induced liver disease and drug use considerations in liver disease

Journal of Pharmacy Practice

Volumn 22, Issue 3, 2009, Pages 278-289

  Kim, Jiwon W ^a   Phongsamran, Paula V ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b USC UNIVERSITY HOSPITAL   (United States)

Author keywords

Dosage adjustment; Drug induced liver disease; Hepatotoxicity; Liver disease

Indexed keywords

AMIODARONE; AMOXICILLIN PLUS CLAVULANIC ACID; ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; AZATHIOPRINE; CARBAMAZEPINE; CHLORPROMAZINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DANTROLENE; ERYTHROMYCIN; ETOPOSIDE; MACROLIDE; METHYLDOPA; MEVINOLIN; MINOCYCLINE; MITOMYCIN; NEFAZODONE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENYTOIN; SULFONAMIDE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; VINBLASTINE; VINCRISTINE;

ALTERNATIVE MEDICINE; CHOLESTASIS; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DISEASE SEVERITY; DRUG METABOLISM; DRUG WITHDRAWAL; FATTY LIVER; GRANULOMATOUS HEPATITIS; HUMAN; IMMUNOALLERGIC HEPA; IMMUNOALLERGIC HEPATITIS; LIPIDOSIS; LIVER CELL DAMAGE; LIVER CLEARANCE; LIVER DISEASE; LIVER FAILURE; LIVER INJURY; LIVER NECROSIS; LIVER VENOOCCLUSIVE DISEASE; REVIEW; SCORING SYSTEM; STATISTICAL MODEL;

EID: 66249144083     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008328696     Document Type: Review

References (68)

1. Kung HC, Hoyert DL, Xu JQ, et al. Deaths: Preliminary data for 2005. Health E-Stats. Hyattsville, MD: National Center for Health Statistics. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr56/nvsr56-10.pdf. Accessed August 15, 2008.
2. Dienstag JL, McHutchison JG American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology. 2006 ; 130: 225-230. (Pubitemid 43049855)
3. Anthony PP, Ishak KG, Nayak NC, et al. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol. 1978 ; 31: 395-441. (Pubitemid 8333033)
4. Child C., Turcotte J. Surgery and portal hypertension. In: Child CG, ed. The Liver and Portal Hypertension. Philadelphia, PA: WB Saunders ; 1964: 50-72.
5. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the esophagus for bleeding esophageal varices. Bvr J Surg. 1973 ; 60: 646-649.
6. Fernandez-Esparrach G., Sanchez-Fueyo A., Gines P., et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol. 2001 ; 34: 46-52. (Pubitemid 32102551)
7. Malinchoc M., Kamath PS, Grodon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology. 2003 ; 31: 864-871.
8. Merkel C., Bolognesi M., Bellon S., et al. Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. Gut. 1992 ; 33: 836-842.
9. Salerno F., Borroni G., Moster P., et al. Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation: a prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. J Hepatol. 1996 ; 25: 474-480.
10. Zoli M., Iervese T., Mercekl C., et al. Prognostic significant of portal hemodynamics in patients with compensated cirrhosis. J Hepatol. 1993 ; 17: 56-61. (Pubitemid 23037978)
11. Kamath PS, Wiesner RH, Malinchoc M., et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001 ; 33: 464-70. (Pubitemid 32119037)
12. Wiesner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gatroenterology. 2003 ; 124: 91-96. (Pubitemid 36055342)
13. Angermayr B., Cejna M., Karnel F., et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut. 2003 ; 52: 879-885. (Pubitemid 36613497)
14. Schepke M., Roth F., Fimmers R., et al. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing trnasjugular intrahepatic portosystemic shunting. Am J Gastroenterol. 2003 ; 98: 1167-1174. (Pubitemid 36733783)
15. Bajaj JS, Saeian K. MELD score does not discriminate against patients with hepatic encephalopathy. Dig Dis Sci. 2005 ; 50: 753-756. (Pubitemid 40558472)
16. Freeman RB MELD: the holy grail of organ allocation? J Hepatol. 2005 ; 42: 16j - 20j. (Pubitemid 40038893)
17. Freeman RB, Wiesner RH, Edwards E., et al. Results of the first year of the new liver allocation plan. Liver Transpl. 2004 ; 10: 7-15. (Pubitemid 38885887)
18. Freeman RB, Wiesner RH, Harper A., et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl. 2002 ; 8: 851-858.
19. Lee WM Drug-induced acute liver failure in the United States 2005: results from the U.S. Acute Liver Failure Study Group. FDA-PHRMA-AASLD Hepatotoxicity Steering Committee meeting 28 January 2005.
20. Sgro C., Clinard F., Ouazir K., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002 ; 36: 451-455.
21. Zimmerman HJ Drug-induced liver disease. Clin Liver Dis. 2000 ; 4: 73-96. (Pubitemid 33041487)
22. Kaplowitz N., DeLeve LD Drug-induced Liver Disease. 2 nd ed. New York, NY: Informa Healthcare ; 2007.
23. Larry D. Drug-induced liver diseases. J Hepatol. 2000 ; 32 (suppl 1). 77-88. (Pubitemid 30123626)
24. Lewis JH Drug-induced liver disease. Med Clin North Am. 2000 ; 84: 1275-1311.
25. McDonald GB, Hinds MS, Fisher LD, et al. Venoocclusive disease following bone marrow transplantation: a cohort of 355 patients. Ann Intern Med. 1993 ; 118: 255-267.
26. Edmondson HA, Henderson B., Benton B. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med. 1976 ; 294: 470-472.
27. Stedman C. Herbal toxicity. Semin Liver Dis. 2003 ; 22: 195-206.
28. Valla D., Benhamou JP Drug-induced vascular and sinusoidal lesions of the liver. Clin Gastroenterol. 1988 ; 2: 481-500. (Pubitemid 18203342)
29. Horowitz RS, Feldhaus K., Dart RC, et al. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med. 1996 ; 156: 899-903. (Pubitemid 26120595)
30. Humberston CL, Akhtar J., Krenzelok EP Acute hepatitis induced by kava kava. J Clin Toxicol. 2003 ; 41: 109-113. (Pubitemid 36520458)
31. Seeff LB Herbal hepatotoxicity. Clin Liver Dis. 2007 ; 11: 577-596. (Pubitemid 47302344)
32. Stickel F., Patsenker E., Schuppan D. Herbal hepatotoxicity. J Hepatol. 2005 ; 43: 901-910. (Pubitemid 41414517)
33. Gloro R., Hourmand-Ollivier I., Mosquet B., et al. Fulminant hepatitis during self-medication with hydroalcoholic extract of green tea. Eur J Gastroenterol Hepatol. 2005 ; 17: 1135-1137. (Pubitemid 41424011)
34. Bonkovsky HL Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis). Ann Intern Med. 2006 ; 144: 68-71. (Pubitemid 46780727)
35. Molinari M., Watt KD, Kruszyna T., et al. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl. 2006 ; 12: 1892-1895.
36. Stevens T., Qadri A., Zein NN Two patients with acute liver injury associated with use of the herbal weight-loss supplement Hydroxycut. Arch Intern Med. 2005 ; 142: 477-478. (Pubitemid 40365441)
37. Delco F., Tchambaz L., Schlienger R., et al. Dose adjustment in patients with liver disease. Drug Safety. 2005 ; 28: 529-545. (Pubitemid 41003057)
38. Morgan DJ, McLean AJ Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet. 1995 ; 29: 370-391.
39. Verbeeck RK, Horsmans Y. Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci. 1998 ; 20: 183-192. (Pubitemid 28500179)
40. Ohkubo H., Okuda K., Iida S., et al. Role of portal and splenic vein shunts and impaired hepatic extraction in the elevated serum bile acids in liver cirrhosis. Gastroenterology. 1984 ; 86: 514-520. (Pubitemid 14154662)
41. Shull JH, Wilkinson GR, Johnson R., et al. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med. 1976 ; 84: 420-425.
42. Ghabrial H., Desmond PV, Watson KJ, et al. The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol. 1986 ; 30: 93-97. (Pubitemid 16166991)
43. Pentikainen PJ, Valisalmi L., Himberg JJ, et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol. 1989 ; 29: 272-277. (Pubitemid 19087927)
44. Andreasen PB, Hendel J., Greisen G., et al. Pharmacokinetics of diazepam in disordered liver function. Eur J Clin Pharmacol. 1976 ; 10: 115-120.
45. Rodriquez A., Martin A., Oterino JA, et al. Renal function in compensated hepatic cirrhosis: effects of an amino acid infusion and relationship with nitric acid. Dig Dis. 1999 ; 17: 235-240. (Pubitemid 30198258)
46. Woitas RP, Heller J., Stoffel-Wagner B., et al. Renal functional reserve and nitric oxide in in patients with compensated liver cirrhosis. Hepatology. 1997 ; 26: 858-864. (Pubitemid 27413649)
47. Orlando R., Floreani M., Padrini R., et al. Evaluation of measured and calculated creatinine clearances as glomerular filtration markers in different stages of liver cirrhosis. Clin Nephrol. 1999 ; 51: 341-347. (Pubitemid 29261693)
48. Caregaro L., Menon F., Angeli P., et al. Limitations of serum creatinine level and creatinine clearance as filtration markers in cirrhosis. Arch Intern Med. 1994 ; 154: 201-205. (Pubitemid 24032194)
49. Ruhnke M., Yeates RA, Pfaff G., et al. Single-dose pharmacokinetics of fluconazole in patients with liver cirrhosis. J Antimicrob Chemother. 1995 ; 35: 641-647.
50. Orlando R., Sawadogo A., Miglioli PA, et al. Oral disposition kinetics of ofloxacin in patients with compensated liver cirrhosis. Chemoterapy. 1992 ; 38: 1-6.
51. Koren G., Beatty K., Seto A., et al. The effect of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother. 1992 ; 26: 363-371.
52. Lewis JH, Mortensen ME, Zweig S., et al. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007 ; 46: 1453-1463. (Pubitemid 350155527)
53. Khorashadi S., Hasson NK, Cheung RC Incidence of statin hepatotoxicity in patients with hepatitis C. Clin Gastroenterol Hepatol. 2006 ; 4: 902-907. (Pubitemid 43994535)
54. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet. 1999 ; 37: 399-431.
55. Horvath AM, Olson SC, Ferry JJ, et al. Pharmacokinetics of quinalapril and its active metabolite, quinalaprilat, in patients with hepatic impairment. J Clin Pharmacol. 1988 ; 28: 917.
56. Ohnishi A., Tsuboi Y., Ishizaki T. Kinetics and dynamics of enalapril in patients with liver cirrhosis. Clin Pharmacol Ther. 1989 ; 45: 657-665. (Pubitemid 19184178)
57. Whiting-O'Keefe QE, Fye KH, Sack KD Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med. 1991 ; 90: 711-716.
58. Slattery JT, Nelson SD, Thummel KE The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther. 1996 ; 60: 241-246. (Pubitemid 26354444)
59. Gronhagen-Riska C., Hellstrom PE, Froseth B. Predisposing factors in hepatitis induced by isoniazidrifampin treatment of tuberculosis. Am Rev Respir Dis. 1978 ; 118: 461-466. (Pubitemid 9027187)
60. Krahenbuhl S., Mang G., Kupferschmidt H., et al. Plasma and hepatic carnitine and coenzyme A pools in a patients with fatal, valproate induced hepatotoxicity. Gut. 1995 ; 37: 140-143.
61. Hasselstrom J., Eriksson S., Persson A., et al. The metabolism and bioavailability of morphine in patients with severe liver cirrhosis. Br J Clin Pharmacol. 1990 ; 29: 289-297. (Pubitemid 20129020)
62. Crotty B., Watson KJ, Desmond PV, et al. Hepatic extraction of morphine is impaired in cirrhosis. Eur J Clin Pharmacol. 1989 ; 36: 501-506. (Pubitemid 19135214)
63. Gines P., Arrovo V., Rodes J. Pharmacotherapy of ascites associated with cirrhosis. Drugs. 1992 ; 43: 316-332.
64. Singh N., Yu VL, Mieles LA, et al. Beta-lactam antibiotic-induced leucopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease. Am J Med. 1993 ; 94: 251-256. (Pubitemid 23074798)
65. Moore RD, Smith CR, Lietman PS Increased risk of renal dysfunction due to interaction of liver disease and aminoglycosides. Am J Med. 1986 ; 80: 1093-1097.
66. Lucena MI, Andrade RJ, Cabello MR, et al. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol. 1995 ; 22: 189-196.
67. Cancidas [package insert]. Whitehouse Station, NJ: Merck & Co, Inc ; 2008.
68. Tygacil [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals, Inc ; 2006.